Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 533Squamous Cell Carcinoma of Head and Neck 274Head and Neck Neoplasms 253Lung Neoplasms 238Uterine Cervical Neoplasms 178Stomach Neoplasms 168Esophageal Neoplasms 160Nasopharyngeal Carcinoma 123Urinary Bladder Neoplasms 116Esophageal Squamous Cell Carcinoma 115Neoplasms 113Small Cell Lung Carcinoma 104Breast Neoplasms 92Neoplasm Metastasis 90Ovarian Neoplasms 89Cholangiocarcinoma 76Carcinoma, Squamous Cell 76Pancreatic Neoplasms 72Biliary Tract Neoplasms 70Mesothelioma, Malignant 57Oropharyngeal Neoplasms 56Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 47Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 45Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Triple Negative Breast Neoplasms 38

Interventions

Nivolumab 20Ipilimumab 10Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Cancer × Cisplatin × Clear all
NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Suzhou Transcenta Therapeutics Co., Ltd.

Phase 1/2 Recruiting
320 enrolled

Advanced Cancer

NCT00507962 2012-08-02

Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement

M.D. Anderson Cancer Center

Phase 1 Completed
51 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡